Brief: Karolinska Development Portfolio Company Boost Pharma Announces Positive Top-Line Results From Phase 1/2 Study

Kdventures AB

17/09/2024 07:09

Sept 17 (Reuters) - Karolinska Development AB  KDEV.ST :
    * KAROLINSKA DEVELOPMENTS PORTFOLIO COMPANY BOOST PHARMA
ANNOUNCES
POSITIVE TOP-LINE RESULTS FROM A PHASE 1/2 STUDY WITH OVER 75%
REDUCTION OF FRACTURE RATES IN CHILDREN WITH RARE BONE DISEASE
    * TREATMENT WAS SAFE AND WELL TOLERATED AND THAT FRACTURE
RATES
WERE REDUCED BY OVER 75%

Source text for Eikon:  ID:nGNE3NMWCR 
Further company coverage:  KDEV.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com;))